News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,829 Results
Type
Article (41633)
Company Profile (464)
Press Release (659732)
Section
Business (208410)
Career Advice (2012)
Deals (35944)
Drug Delivery (94)
Drug Development (83319)
Employer Resources (169)
FDA (16332)
Job Trends (15047)
News (352128)
Policy (32986)
Tag
Academia (2619)
Alliances (50634)
Alzheimer's disease (1284)
Approvals (16257)
Artificial intelligence (150)
Bankruptcy (361)
Best Places to Work (11749)
Biotechnology (350)
Breast cancer (140)
Cancer (1180)
Cardiovascular disease (109)
Career advice (1676)
Cell therapy (256)
Clinical research (66112)
Collaboration (429)
Compensation (214)
COVID-19 (2593)
C-suite (107)
Data (1195)
Diabetes (161)
Diagnostics (6215)
Earnings (86071)
Employer resources (147)
Events (113178)
Executive appointments (332)
FDA (16911)
Funding (390)
Gene therapy (198)
GLP-1 (617)
Government (4412)
Healthcare (19009)
Infectious disease (2679)
Inflammatory bowel disease (115)
Interviews (310)
IPO (16587)
Job creations (3695)
Job search strategy (1432)
Layoffs (441)
Legal (7930)
Lung cancer (178)
Manufacturing (184)
Medical device (13335)
Medtech (13340)
Mergers & acquisitions (19446)
Metabolic disorders (435)
Neuroscience (1588)
NextGen Class of 2024 (6733)
Non-profit (4533)
Northern California (1559)
Obesity (248)
Opinion (198)
Patents (109)
People (57675)
Phase I (20723)
Phase II (29181)
Phase III (21584)
Pipeline (479)
Postmarket research (2592)
Preclinical (8895)
Radiopharmaceuticals (252)
Rare diseases (245)
Real estate (5999)
Regulatory (22003)
Research institute (2404)
Resumes & cover letters (352)
Southern California (1362)
Startups (3747)
United States (14380)
Vaccines (570)
Weight loss (185)
Date
Today (111)
Last 7 days (390)
Last 30 days (3337)
Last 365 days (36592)
2024 (34395)
2023 (41013)
2022 (52276)
2021 (56765)
2020 (54925)
2019 (47419)
2018 (35697)
2017 (33024)
2016 (32347)
2015 (38397)
2014 (32185)
2013 (27109)
2012 (29222)
2011 (29865)
2010 (27992)
Location
Africa (731)
Arizona (201)
Asia (38565)
Australia (6410)
California (3550)
Canada (1344)
China (273)
Colorado (155)
Connecticut (169)
Europe (84086)
Florida (485)
Georgia (122)
Illinois (365)
Indiana (207)
Kansas (99)
Maryland (610)
Massachusetts (2840)
Michigan (162)
Minnesota (283)
New Jersey (1012)
New York (1012)
North Carolina (773)
Northern California (1559)
Ohio (144)
Pennsylvania (877)
South America (1105)
Southern California (1362)
Texas (511)
Utah (94)
Washington State (385)
701,829 Results for "rapt therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
RAPT Therapeutics Reports First Quarter 2024 Financial Results
RAPT Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.
May 9, 2024
·
7 min read
Press Releases
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
November 13, 2024
·
6 min read
Drug Development
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
RAPT Therapeutics, Inc. (Nasdaq: RAPT) today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the company’s Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma.
February 20, 2024
·
4 min read
Press Releases
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
November 11, 2024
·
3 min read
Business
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsCompany maintains solid cash position of $158.9 million
RAPT Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2023.
March 7, 2024
·
7 min read
Business
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
RAPT Therapeutics, Inc. today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations.
February 13, 2024
·
2 min read
Drug Development
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
RAPT Therapeutics, Inc. (Nasdaq: RAPT) today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (HNSCC) whose disease progressed despite previous treatment with CPI therapy (CPI-experienced).
April 9, 2024
·
6 min read
Press Releases
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
August 8, 2024
·
8 min read
Pipeline
RAPT Crashes After Axing Atopic Dermatitis, Asthma Hopeful, Cites Liver Injury
In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.
November 11, 2024
·
2 min read
·
Tristan Manalac
Biotech Bay
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November 2023
RAPT Therapeutics, Inc. announced that members of the RAPT management team will participate in the following investor conferences in November.
November 1, 2023
·
1 min read
1 of 70,183
Next
